Bank of America Merrill Lynch downgrades Bristol Myers Squibb (BMY)
Bank of America Merrill Lynch reported on Monday that they have downgraded biopharmaceutical company, Bristol Myers Squibb Co. to ``Neutral.''
Goldman Sachs upgraded Johnson & Johnson from Neutral to Buy, while downgrading Bristol-Myers Squibb Co..